# Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

> **NCT00102050** · PHASE2 · COMPLETED · sponsor: **Nissan Chemical Industries** · enrollment: 390 (—)

## Conditions studied

- Intermittent Claudication
- Peripheral Vascular Disease

## Interventions

- **DRUG:** NM-702 (phosphodiesterase inhibitor)

## Key facts

- **NCT ID:** NCT00102050
- **Lead sponsor:** Nissan Chemical Industries
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 390 (—)
- **Last updated:** 2006-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102050, "Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00102050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*